[IL2401] Cyclin K Degrader-Antibody-Conjugates for Solid Tumors

• Developing the first Cyclin K Degrader as a novel DAC payload, administered via IV injection, intended for use as a first-line monotherapy or in combination with existing first-line therapies 

• The payload demonstrates enhanced potency and broader coverage across various solid tumor cells, with robust Cyclin K degradation observed in cancer cells

• The platform allows for further pipeline expansion through combination with diverse antibodies and linkers

• Designed to overcome resistance mechanisms associated with current therapies